Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2025
FDA concerns over promotional communications
The company's U.S. subsidiary received FDA warning letters concerning promotional materials for Brukinsa and Tevimbra that allegedly failed to include or adequately present required risk information.
2024
Investigation involving a senior executive
A senior executive of the then-named BeiGene was reportedly investigated by Chinese anti-smuggling authorities, reportedly in connection with her prior 15-year tenure at AstraZeneca. The available material does not state a final legal outcome.
2024
Trade-secret lawsuit involving AbbVie
AbbVie filed U.S. federal litigation alleging that BeOne's U.S. subsidiary had stolen trade secrets. The reference material describes the litigation as active but does not provide a final judgment.